Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

Arvinas, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW HAVEN, CONN., JULY 28, 2026 (GLOBE NEWSWIRE) -- ARVINAS, INC. (NASDAQ: ARVN), A BIOTECHNOLOGY COMPANY CREATING A NEW CLASS OF DRUGS BASED ON TARGETED PROTEIN DEGRADATION, TODAY ANNOUNCED THAT MANAGEMENT WILL REVIEW SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE DURING A LIVE WEBCAST ON TUESDAY, AUGUST 4, 2026 AT 8:00 A.M. ET.

ARVINAS TO REPORT SECOND QUARTER 2026 FINANCIAL RESULTS ON AUGUST 4, 2026

NEW HAVEN, CONN., MAY 29, 2026 (GLOBE NEWSWIRE) -- ARVINAS, INC. (NASDAQ: ARVN), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY CREATING A NEW CLASS OF DRUGS BASED ON TARGETED PROTEIN DEGRADATION, TODAY ANNOUNCED THAT MANAGEMENT WILL PARTICIPATE IN A FIRESIDE CHAT AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE ON WEDNESDAY, JUNE 3 AT 9:55 A.M. ET.

ARVINAS TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE

NEW HAVEN, CONN., MAY 18, 2026 (GLOBE NEWSWIRE) -- ARVINAS, INC. (NASDAQ: ARVN), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY WORKING TO CREATE A NEW CLASS OF DRUGS BASED ON TARGETED PROTEIN DEGRADATION, TODAY ANNOUNCED THAT EMPLOYEES ACROSS CONNECTICUT, IN THE GREATER BOSTON AREA, AND AROUND THE COUNTRY, TOOK PART IN THE COMPANY'S FOURTH ARVINAS IMPACT DAY THIS PAST FRIDAY. THIS COMPANY-WIDE DAY OF SERVICE BRINGS EMPLOYEES TOGETHER TO GIVE BACK TO THEIR COMMUNITIES THROUGH VOLUNTEER ACTIVITIES THAT WILL MAKE A MEANINGFUL DIFFERENCE ACROSS THE GREATER NEW HAVEN AREA AND BEYOND.

ARVINAS EMPLOYEES GIVE BACK DURING COMPANY-WIDE IMPACT DAY

 FIRST-EVER FDA APPROVED PROTAC SUPPORTS THE FURTHER DEVELOPMENT AND POTENTIAL OF ARVINAS' PIPELINE   ANNOUNCED FDA APPROVAL OF VEPPANU  (VEPDEGESTRANT) FOR THE TREATMENT OF ESR1M, ER+/HER2- ADVANCED BREAST CANCER   ANNOUNCED SELECTION OF RIGEL PHARMACEUTICALS FOR THE EXCLUSIVE GLOBAL RIGHTS TO VEPPANU   PRESENTED ARV-102 (LRRK2 DEGRADER) PHASE 1 CLINICAL DATA IN PATIENTS WITH PARKINSON'S DISEASE DEMONSTRATING REDUCTION IN ENDOLYSOSOMAL AND NEUROINFLAMMATORY BIOMARKERS IMPLICATED IN PARKINSON'S DISEASE AND PROGRESSIVE SUPRANUCLEAR PALSY   PRESENTED ARV-6723 (HPK1 DEGRADER) PRECLINICAL DATA AT THE AMERICAN ASSOCIATED OF CANCER RESEARCH ANNUAL MEETING DEMONSTRATING THE POTENTIAL TO OVERCOME IMMUNE CHECKPOINT INHIBITOR RESISTANCE IN SOLID TUMORS   INITIATED DOSING WITH ARV-027 (POLYQ-AR DEGRADER) IN PHASE 1 HEALTHY VOLUNTEER TRIAL WITH SINGLE-ASCENDING DOSE DATA ANTICIPATED IN 2H26   COMPANY TO HOST CONFERENCE CALL TODAY AT 8:00 A.M. ET  NEW HAVEN, CONN.

ARVINAS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

 ARVINAS AND PFIZER TO RECEIVE $85 MILLION IN UPFRONT AND TRANSITION PAYMENTS WITH POTENTIAL FOR ADDITIONAL $320 MILLION IN DEVELOPMENT, REGULATORY, AND COMMERCIAL MILESTONES AND TIERED ROYALITES ON NET SALES  NEW HAVEN, CONN., MAY 12, 2026 (GLOBE NEWSWIRE) -- ARVINAS, INC. (NASDAQ: ARVN), A BIOTECHNOLOGY COMPANY CREATING A NEW CLASS OF DRUGS BASED ON TARGETED PROTEIN DEGRADATION, AND PFIZER INC. (NYSE: PFE) HAVE ENTERED INTO A LICENSE AGREEMENT WITH RIGEL PHARMACEUTICALS, INC., A COMMERCIAL STAGE BIOTECHNOLOGY COMPANY FOCUSED ON HEMATOLOGIC DISORDERS AND CANCER, FOR THE EXCLUSIVE GLOBAL DEVELOPMENT, MANUFACTURING, AND COMMERCIALIZATION RIGHTS FOR VEPPANU (VEPDEGESTRANT).

ARVINAS AND PFIZER ENTER INTO A TRANSACTION WITH RIGEL PHARMACEUTICALS FOR THE EXCLUSIVE GLOBAL RIGHTS OF VEPPANU (VEPDEGESTRANT)

NEW HAVEN, CONN., MAY 05, 2026 (GLOBE NEWSWIRE) -- ARVINAS, INC. (NASDAQ: ARVN), A BIOTECHNOLOGY COMPANY WORKING TO CREATE A NEW CLASS OF DRUGS BASED ON TARGETED PROTEIN DEGRADATION, TODAY ANNOUNCED THAT MANAGEMENT WILL REVIEW FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE DURING A LIVE WEBCAST ON TUESDAY, MAY 12, 2026 AT 8:00 A.M.

ARVINAS TO REPORT FIRST QUARTER 2026 FINANCIAL RESULTS ON MAY 12, 2026

PALO ALTO, CALIF.--(BUSINESS WIRE)--GUARDANT HEALTH, INC. (NASDAQ: GH), A LEADING PRECISION ONCOLOGY COMPANY, TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS APPROVED THE GUARDANT360 CDX LIQUID BIOPSY TEST AS A COMPANION DIAGNOSTIC FOR VEPPANU (VEPDEGESTRANT). VEPPANU, JOINTLY DEVELOPED BY ARVINAS, INC. AND PFIZER INC., IS APPROVED FOR THE TREATMENT OF ADULTS WITH ESTROGEN RECEPTOR-POSITIVE (ER+), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-), ESTROGEN RECEPTOR.

GUARDANT HEALTH RECEIVES FDA APPROVAL FOR GUARDANT360 CDX AS A COMPANION DIAGNOSTIC FOR ARVINAS AND PFIZER'S VEPPANU (VEPDEGESTRANT) FOR PATIENTS WITH ER+/HER2- ADVANCED BREAST CANCER WITH ESR1 MUTATIONS

 VEPPANU IS THE FIRST-AND-ONLY FDA-APPROVED PROTAC, A TYPE OF HETEROBIFUNCTIONAL PROTEIN DEGRADER   APPROVAL RECEIVED IN ADVANCE OF FDA-ASSIGNED PDUFA DATE OF JUNE 5, 2026; ARVINAS AND PFIZER REMAIN ON TRACK TO ANNOUNCE SELECTION OF A THIRD PARTY   VEPPANU OFFERS A NEW THERAPEUTIC OPTION IN ER+/HER2-, ESR1-MUTATED ADVANCED OR METASTATIC BREAST CANCER, WHERE TREATMENT RESISTANCE REMAINS A MAJOR CLINICAL CHALLENGE  NEW HAVEN, CONN., MAY 01, 2026 (GLOBE NEWSWIRE) -- ARVINAS, INC. (NASDAQ: ARVN), TODAY WITH ITS PARTNER PFIZER INC. (NYSE: PFE), ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS GRANTED APPROVAL FOR VEPPANU (VEPDEGESTRANT) FOR THE TREATMENT OF ADULTS WITH ESTROGEN RECEPTOR-POSITIVE (ER+)/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-), ESTROGEN RECEPTOR 1 (ESR1)-MUTATED ADVANCED OR METASTATIC BREAST CANCER, AS DETECTED BY AN FDA-AUTHORIZED TEST, WITH DISEASE PROGRESSION FOLLOWING AT LEAST ONE LINE OF ENDOCRINE THERAPY.

ARVINAS ANNOUNCES FDA APPROVAL OF VEPPANU (VEPDEGESTRANT) FOR THE TREATMENT OF ESR1M, ER+/HER2- ADVANCED BREAST CANCER

 ARV-102 REDUCED ENDOLYSOSOMAL AND NEUROINFLAMMATORY BIOMARKERS IMPLICATED IN PARKINSON'S DISEASE AND PROGRESSIVE SUPRANUCLEAR PALSY 

ARVINAS ANNOUNCES POSITIVE PHASE 1 DATA FOR ARV-102 SHOWING GREATER THAN 50% LRRK2 DEGRADATION IN THE CSF OF PATIENTS WITH PARKINSON'S DISEASE TREATED FOR 28 DAYS

 COMPANY TO HIGHLIGHT NEW SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC DATA FROM PHASE 1 CLINICAL TRIAL OF ARV-102 IN PARTICIPANTS WITH PARKINSON'S DISEASE 

ARVINAS TO PRESENT PHASE 1 DATA FOR ARV-102, A PROTAC LRRK2 DEGRADER, IN ORAL SESSION AT THE 2026 INTERNATIONAL CONFERENCE ON ALZHEIMER'S AND PARKINSON'S DISEASES AND RELATED NEUROLOGICAL DISORDERS

Arvinas, Inc.

ARVN

Price

Financial Reports

No items found.

Press Releases

Arvinas, Inc.

ARVN.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

ARVN